WCM
MYGN icon

Wealthcare Capital Management’s Myriad Genetics MYGN Stock Holding History

Wealthcare Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-43
Closed -$1K – 452
2021
Q1 		$1K Buy
+43
New +$1.22K ﹤0.01% 699

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wealthcare Capital Management's MYGN Position: Q2 2021 in Review

Wealthcare Capital Management sold out of Myriad Genetics (MYGN) in Q2 2021, closing a stake of 43 shares — an estimated $1K sold.

Wealthcare Capital Management first reported a position in MYGN in Q1 2021 and held it in 1 quarter. The position peaked at $1K in Q1 2021. 201 funds tracked by Wall St. Rank hold MYGN as of Q2 2021.

  • Wealthcare Capital Management reported no remaining Myriad Genetics position as of Q2 2021 after selling out during the quarter.
  • Wealthcare Capital Management sold 43 Myriad Genetics shares in Q2 2021, an estimated $1K.
  • Wealthcare Capital Management first reported a position in Myriad Genetics in Q1 2021 and held it in 1 quarter.
  • Wealthcare Capital Management's Myriad Genetics position peaked at $1K in Q1 2021.
  • 201 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2021.

Based on Wealthcare Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.